Cancer Therapy

You have full text access to this OnlineOpen article

TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer†

  1. Zhiwei Wang1,
  2. Wen Song2,
  3. Amro Aboukameel2,
  4. Mussop Mohammad2,
  5. Guoping Wang3,
  6. Sanjeev Banerjee1,
  7. Dejuan Kong1,
  8. Shaomeng Wang3,
  9. Fazlul H. Sarkar1,
  10. Ramzi M. Mohammad2,‡,*

Article first published online: 4 JUN 2008

DOI: 10.1002/ijc.23610

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 4, pages 958–966, 15 August 2008

Additional Information

How to Cite

Wang, Z., Song, W., Aboukameel, A., Mohammad, M., Wang, G., Banerjee, S., Kong, D., Wang, S., Sarkar, F. H. and Mohammad, R. M. (2008), TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int. J. Cancer, 123: 958–966. doi: 10.1002/ijc.23610

Author Information

  1. 1

    Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI

  2. 2

    Department of Internal Medicine, Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI

  3. 3

    Department of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI

  1. ‡

    Fax: +313-576-8389.

*Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 732 HWCRC, 4100 John R. Street, Detroit, MI 48201

  1. †

    Conflict of Interest: University of Michigan has filed a patent on TW-37, which has been licensed by Ascenta Therapeutics Inc. University of Michigan and Dr. Shaomeng Wang own equity in Ascenta. Dr. Shaomeng Wang also serves as a consultant for Ascenta and is the principal investigator on research contract from Ascenta to University of Michigan.

Publication History

  1. Issue published online: 12 JUN 2008
  2. Article first published online: 4 JUN 2008
  3. Manuscript Accepted: 11 MAR 2008
  4. Manuscript Received: 7 JUL 2007

Funded by

  • National Cancer Institute, NIH. Grant Number: R01CA109389
  • NIH. Grant Number: 5R01CA101870
  • NIH. Grant Number: P30CA22453
  • NIH. Grant Number: U19CA11317
  • Department of Defense Breast Cancer Program. Grant Number: BC0009140

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (788K)

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
    Direct Link:
  • 2
    Mohammad RM,Wang S,Banerjee S,Wu X,Chen J,Sarkar FH. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas 2005; 31: 317–24.
  • 3
    Giovannetti E,Mey V,Nannizzi S,Pasqualetti G,Del TM,Danesi R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 2006; 5: 1387–95.
  • 4
    Adams JM,Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324–37.
  • 5
    Mohammad RM,Banerjee S,Li Y,Aboukameel A,Kucuk O,Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006; 106: 1260–8.
    Direct Link:
  • 6
    Garcea G,Neal CP,Pattenden CJ,Steward WP,Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41: 2213–36.
  • 7
    Verhaegen M,Bauer JA,Martin dl V,Wang G,Wolter KG,Brenner JC,Nikolovska-Coleska Z,Bengtson A,Nair R,Elder JT,Van BM,Carey TE, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66: 11348–59.
  • 8
    Zeitlin BD,Joo E,Dong Z,Warner K,Wang G,Nikolovska-Coleska Z,Wang S,Nor JE. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006; 66: 8698–706.
  • 9
    Mohammad RM,Goustin AS,Aboukameel A,Chen B,Banerjee S,Wang G,Nikolovska-Coleska Z,Wang S,Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007; 13: 2226–35.
  • 10
    Ricca A,Biroccio A,Del BD,Mackay AR,Santoni A,Cippitelli M. Bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 2000; 86: 188–96.
    Direct Link:
  • 11
    Karl E,Warner K,Zeitlin B,Kaneko T,Wurtzel L,Jin T,Chang J,Wang S,Wang CY,Strieter RM,Nunez G,Polverini PJ, et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 2005; 65: 5063–9.
  • 12
    Wang G,Nikolovska-Coleska Z,Yang CY,Wang R,Tang G,Guo J,Shangary S,Qiu S,Gao W,Yang D,Meagher J,Stuckey J, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139–42.
  • 13
    Wang Z,Banerjee S,Li Y,Rahman KM,Zhang Y,Sarkar FH. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-{kappa}B, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778–84.
  • 14
    Wang Z,Sengupta R,Banerjee S,Li Y,Zhang Y,Rahman KM,Aboukameel A,Mohammad R,Majumdar AP,Abbruzzese JL,Sarkar FH. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res 2006; 66: 7653–60.
  • 15
    Xu L,Kong D,Zhu L,Zhu W,Andrews DW,Kuo TH. Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Mol Cell Biochem 2007; 295: 153–65.
  • 16
    Wang Z,Banerjee S,Kong D,Li Y,Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293–300.
  • 17
    Mohammad RM,Dugan MC,Mohamed AN,Almatchy VP,Flake TM,Dergham ST,Shields AF,Al-Katib AA,Vaitkevicius VK,Sarkar FH. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998; 16: 19–25.
  • 18
    Bae IH,Park MJ,Yoon SH,Kang SW,Lee SS,Choi KM,Um HD. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res 2006; 66: 4991–5.
  • 19
    Neri A,Marrelli D,Roviello F,DeMarco G,Mariani F,DeStefano A,Megha T,Caruso S,Corso G,Cioppa T,Pinto E. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer. Breast Cancer Res Treat 2006; 99: 77–83.
  • 20
    Choi J,Choi K,Benveniste EN,Rho SB,Hong YS,Lee JH,Kim J,Park K. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res 2005; 65: 5554–60.
  • 21
    Regula KM,Ens K,Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J Biol Chem 2002; 277: 38676–82.
  • 22
    Moissac D DE,Mustapha S,Greenberg AH,Kirshenbaum LA. Bcl-2 activates the transcription factor NFkappaB through the degradation of the cytoplasmic inhibitor IkappaBalpha. J Biol Chem 1998; 273: 23946–51.
  • 23
    Ohno I,Gukovskaya AS,Odinkova IV,Batra RK,Pandol SJ. Bcl-2/Bcl-xL mediate ROS production in pancreatic cancer cells leading to the inhibition of apoptosis (Abstract 4581). 97th AACR Annual Meeting, Los Angeles 2007.
  • 24
    Sclabas GM,Fujioka S,Schmidt C,Evans DB,Chiao PJ. NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer 2003; 33: 15–26.
  • 25
    Mortenson MM,Galante JG,Gilad O,Schlieman MG,Virudachalam S,Kung HJ,Bold RJ. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007; 102: 1171–9.
    Direct Link:
  • 26
    Van WC. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13: 1076–82.
  • 27
    Gilmore TD. Multiple myeloma: lusting for NF-kappaB. Cancer Cell 2007; 12: 95–7.
  • 28
    Curran S,Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621–30.
  • 29
    Dong Z,Bonfil RD,Chinni S,Deng X,Trindade Filho JC,Bernardo M,Vaishampayan U,Che M,Sloane BF,Sheng S,Fridman R,Cher ML. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005; 166: 1173–86.
  • 30
    Nagakawa Y,Aoki T,Kasuya K,Tsuchida A,Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 2002; 24: 169–78.
  • 31
    Takada Y,Bhardwaj A,Potdar P,Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23: 9247–58.
  • 32
    Takada Y,Kobayashi Y,Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 2005; 280: 17203–12.
View Full Article (HTML) Get PDF (788K)